Aclarion Stock Today

ACON Stock  USD 0.18  0.01  5.26%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 85

 
High
 
Low
Very High
Aclarion is selling at 0.18 as of the 8th of September 2024; that is 5.26 percent decrease since the beginning of the trading day. The stock's open price was 0.19. Aclarion has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Aclarion are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of July 2024 and ending today, the 8th of September 2024. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
22nd of April 2022
Category
Healthcare
Classification
Health Care
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy in the United States. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California. Aclarion operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. The company has 9.61 M outstanding shares of which 230.88 K shares are presently shorted by private and institutional investors with about 0.59 trading days to cover. More on Aclarion

Moving together with Aclarion Stock

  0.73GH Guardant HealthPairCorr
  0.87OM Outset MedicalPairCorr
  0.61DXCM DexCom IncPairCorr

Moving against Aclarion Stock

  0.87CAH Cardinal HealthPairCorr
  0.84DOCS DoximityPairCorr
  0.82EVH Evolent HealthPairCorr
  0.8VEEV Veeva Systems ClassPairCorr
  0.31DHR DanaherPairCorr

Aclarion Stock Highlights

President CEOBrent Ness
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Health Information Services, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Aclarion can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aclarion's financial leverage. It provides some insight into what part of Aclarion's total assets is financed by creditors.
Liquidity
Aclarion currently holds 1.13 M in liabilities. Aclarion has a current ratio of 3.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aclarion's use of debt, we should always consider it together with its cash and equity.

Begin Period Cash Flow

813,053
Aclarion (ACON) is traded on NASDAQ Exchange in USA. It is located in 8181 Arista Place, Broomfield, CO, United States, 80021 and employs 4 people. Aclarion is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.76 M. Aclarion conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 9.61 M outstanding shares of which 230.88 K shares are presently shorted by private and institutional investors with about 0.59 trading days to cover. Aclarion currently holds about 3.79 M in cash with (3.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aclarion Probability Of Bankruptcy
Ownership Allocation
Aclarion shows 12.06 percent of its outstanding shares held by insiders and 3.65 percent owned by other corporate entities.
Check Aclarion Ownership Details

Aclarion Stock Institutional Holders

InstituionRecorded OnShares
Virtu Financial Llc2024-03-31
115.2 K
Two Sigma Securities, Llc2024-06-30
32.1 K
Hrt Financial Llc2024-03-31
28.6 K
Ground Swell Capital, Llc2024-06-30
12.9 K
Tower Research Capital Llc2024-03-31
5.4 K
Bank Of America Corp2024-03-31
100.0
Wells Fargo & Co2024-06-30
0.0
View Aclarion Diagnostics

Aclarion Historical Income Statement

At this time, Aclarion's Other Operating Expenses is very stable compared to the past year. As of the 8th of September 2024, Research Development is likely to grow to about 886.2 K, while Net Interest Income is likely to drop (638.5 K). View More Fundamentals

Aclarion Stock Against Markets

Already Invested in Aclarion?

The danger of trading Aclarion is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aclarion is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aclarion. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aclarion is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Information and Resources on Investing in Aclarion Stock

When determining whether Aclarion is a strong investment it is important to analyze Aclarion's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aclarion's future performance. For an informed investment choice regarding Aclarion Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclarion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in Aclarion Stock, please use our How to Invest in Aclarion guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclarion. If investors know Aclarion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclarion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.13)
Revenue Per Share
0.015
Quarterly Revenue Growth
(0.36)
Return On Assets
(1.15)
Return On Equity
(7.14)
The market value of Aclarion is measured differently than its book value, which is the value of Aclarion that is recorded on the company's balance sheet. Investors also form their own opinion of Aclarion's value that differs from its market value or its book value, called intrinsic value, which is Aclarion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclarion's market value can be influenced by many factors that don't directly affect Aclarion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclarion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclarion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclarion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.